WO1998030232A1 - Procedes et compositions de prevention de maladies auto-immunes - Google Patents
Procedes et compositions de prevention de maladies auto-immunes Download PDFInfo
- Publication number
- WO1998030232A1 WO1998030232A1 PCT/CA1998/000015 CA9800015W WO9830232A1 WO 1998030232 A1 WO1998030232 A1 WO 1998030232A1 CA 9800015 W CA9800015 W CA 9800015W WO 9830232 A1 WO9830232 A1 WO 9830232A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agonist
- cells
- antibody
- pharmaceutical composition
- transplant
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title abstract description 10
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 91
- 238000011161 development Methods 0.000 claims abstract description 31
- 239000000556 agonist Substances 0.000 claims abstract description 21
- 108091008034 costimulatory receptors Proteins 0.000 claims abstract description 6
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 43
- 229940123205 CD28 agonist Drugs 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 9
- 210000004153 islets of langerhan Anatomy 0.000 claims description 8
- 210000000496 pancreas Anatomy 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 94
- 210000004027 cell Anatomy 0.000 description 44
- 238000011282 treatment Methods 0.000 description 41
- 102000004388 Interleukin-4 Human genes 0.000 description 34
- 108090000978 Interleukin-4 Proteins 0.000 description 34
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 29
- 210000004241 Th2 cell Anatomy 0.000 description 24
- 230000004940 costimulation Effects 0.000 description 24
- 230000003393 splenic effect Effects 0.000 description 24
- 206010012601 diabetes mellitus Diseases 0.000 description 17
- 102100037850 Interferon gamma Human genes 0.000 description 16
- 108010074328 Interferon-gamma Proteins 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 15
- 241000699800 Cricetinae Species 0.000 description 14
- 230000002062 proliferating effect Effects 0.000 description 13
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 230000017307 interleukin-4 production Effects 0.000 description 10
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 230000004043 responsiveness Effects 0.000 description 9
- 238000012546 transfer Methods 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000006052 T cell proliferation Effects 0.000 description 8
- 108091008874 T cell receptors Proteins 0.000 description 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000004073 interleukin-2 production Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 7
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000004046 hyporesponsiveness Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 230000003442 weekly effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 5
- 240000005809 Prunus persica Species 0.000 description 5
- 235000006040 Prunus persica var persica Nutrition 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000000139 costimulatory effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 3
- 108700031361 Brachyury Proteins 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 3
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000001904 diabetogenic effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000002992 thymic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241001092081 Carpenteria Species 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 101100341510 Mus musculus Itgal gene Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- VIYFPAMJCJLZKD-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate Chemical compound [Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 VIYFPAMJCJLZKD-UHFFFAOYSA-L 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004524 haematopoietic cell Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- FRZJZRVZZNTMAW-UHFFFAOYSA-N n,n-diethyl-3-(hydroxymethyl)benzamide Chemical compound CCN(CC)C(=O)C1=CC=CC(CO)=C1 FRZJZRVZZNTMAW-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003234 polygenic effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000015055 susceptibility to multiple sclerosis Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
Definitions
- Truncated versions of monoclonal antibodies may also be produced by recombinant techniques in which plasmids are generated which express the desired monoclonal antibody fragment (s) in a suitable host. Antibodies specific for mutagenic epitopes can also be generated.
- compositions for the prevention of autoimmune diseases in mammals.
- IFN- ⁇ remained essentially unaltered in these mice.
- Committed autoreactive cells including Thl cells, may accumulate in pancreatic islets but the functions of IL-4 predominate to inhibit IFN- ⁇ mediated ⁇ cell damage.
- FACS analyses of the phenotype and surface expression of various cell adhesion molecules in anti- CD28 treated and control NOD mice at 8-25 weeks of age also indicated that anti-CD28 mAb treatment did not interfere with the migration of diabetogenic T cells to pancreatic islets (data not shown) .
- the levels of surface expression of LFA-1, L-selectin and CD44 on the surface of splenic T cells did not suffer significantly between untreated and anti-CD28 treated NOD mice.
- CTLL-2 cells 1.5 x 10 4
- Ct.4S cells 5 x 10 3
- Cell proliferation was assessed by addition of [ 3 H] -thymidine for 8 h prior to termination of culture, and [ 3 H] thymidine incorporation was determined as above.
- Anti-CD28 mAb also significantly enhanced the NOD, and to a lesser extent the BALB/c, anti-CD3-induced splenic T cell proliferative response (Figure IB) .
- NOD and BALB/c splenic T cells were less responsive to CD28 costimulation (in terms of fold increases) than thymocytes from these mice, consistent with the notion that primed and naive T cells have different requirements for costimulation. Whereas primed splenic T cells require only TCR engagement to proliferate and produce IL-2, naive thymocytes require at least one additional costimulatory signal for optimal proliferation.
- NOD and BALB/c thymocytes obtained from 8 week old mice were activated by plate bound anti-CD3 in the absence or presence of 1 ⁇ g/ml soluble anti-CD28 mAb (optimal concentration) .
- Culture supernatants were removed, diluted and assayed for their IL-2 and IL-4 content by stimulation of proliferation of the CTLL-2 and CT.4S T cell lines, respectively.
- the results are shown in Figure 1C and ID.
- the CTLL-2 cpm values of [ 3 H] thymidine incorporation for anti-CD3 activated NOD and BALC/c T cells represented by the highest supernatant dilution were 9,064 ⁇ 1,246 and 3,715 ⁇ 940, respectively.
- the results of triplicate cultures are expressed as the mean values ⁇ SD, and are representative of four different experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention porte sur des procédés et des compositions visant à prévenir le développement de maladies auto-immunes chez des sujets sensibles et à prolonger l'acceptation des greffes de tissus par l'administration d'un agoniste de récepteur costimulant CD28 des lymphocytes T.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/341,407 US6841152B1 (en) | 1997-01-10 | 1998-01-12 | Methods for protecting against autoimmune diabetes |
| EP98900502A EP1015016A1 (fr) | 1997-01-10 | 1998-01-12 | Procedes et compositions de prevention de maladies auto-immunes |
| CA002276733A CA2276733A1 (fr) | 1997-01-10 | 1998-01-12 | Procedes et compositions de prevention de maladies auto-immunes |
| AU55462/98A AU5546298A (en) | 1997-01-10 | 1998-01-12 | Methods and compositions for preventing autoimmune disease |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002194814A CA2194814A1 (fr) | 1997-01-10 | 1997-01-10 | Stimulation des cellules t protectrices pour prevenir les maladies auto-immunes |
| CA2,194,814 | 1997-01-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998030232A1 true WO1998030232A1 (fr) | 1998-07-16 |
Family
ID=4159630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1998/000015 WO1998030232A1 (fr) | 1997-01-10 | 1998-01-12 | Procedes et compositions de prevention de maladies auto-immunes |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6841152B1 (fr) |
| EP (1) | EP1015016A1 (fr) |
| AU (1) | AU5546298A (fr) |
| CA (1) | CA2194814A1 (fr) |
| WO (1) | WO1998030232A1 (fr) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1125585A1 (fr) * | 1999-08-30 | 2001-08-22 | Japan Tobacco Inc. | Traitements de maladies immunitaires |
| WO2003078468A2 (fr) * | 2002-03-13 | 2003-09-25 | Tegenero Ag | Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0426644D0 (en) * | 2004-12-03 | 2005-01-05 | Univ Aberdeen | T-cell modulation |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005541A1 (fr) * | 1988-11-23 | 1990-05-31 | The Regents Of The University Of Michigan | Immunotherapie mettant en ×uvre la stimulation de la cd28 |
| WO1992000092A1 (fr) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand pour recepteur a cd28 sur des lymphocytes b et procedes |
| WO1993019767A1 (fr) * | 1992-04-07 | 1993-10-14 | The Regents Of The University Of Michigan | Immunoregulation recourant a la voie d'acces du cd28 |
| WO1994028912A1 (fr) * | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Immunosuppression recourant a la voie d'acces du cd28 |
| WO1995003408A1 (fr) * | 1993-07-26 | 1995-02-02 | Dana-Farber Cancer Institute | B7-2: contre-recepteur de ctla4/cd28 |
| WO1995005464A1 (fr) * | 1993-08-16 | 1995-02-23 | Arch Development Corporation | B7-2: contre recepteur de ctla4/cd28 |
| WO1996014865A1 (fr) * | 1994-11-10 | 1996-05-23 | Repligen Corporation | Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse |
-
1997
- 1997-01-10 CA CA002194814A patent/CA2194814A1/fr not_active Abandoned
-
1998
- 1998-01-12 EP EP98900502A patent/EP1015016A1/fr not_active Withdrawn
- 1998-01-12 WO PCT/CA1998/000015 patent/WO1998030232A1/fr not_active Application Discontinuation
- 1998-01-12 AU AU55462/98A patent/AU5546298A/en not_active Abandoned
- 1998-01-12 US US09/341,407 patent/US6841152B1/en not_active Expired - Fee Related
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005541A1 (fr) * | 1988-11-23 | 1990-05-31 | The Regents Of The University Of Michigan | Immunotherapie mettant en ×uvre la stimulation de la cd28 |
| WO1992000092A1 (fr) * | 1990-07-02 | 1992-01-09 | Bristol-Myers Squibb Company | Ligand pour recepteur a cd28 sur des lymphocytes b et procedes |
| WO1993019767A1 (fr) * | 1992-04-07 | 1993-10-14 | The Regents Of The University Of Michigan | Immunoregulation recourant a la voie d'acces du cd28 |
| WO1994028912A1 (fr) * | 1993-06-10 | 1994-12-22 | The Regents Of The University Of Michigan | Immunosuppression recourant a la voie d'acces du cd28 |
| WO1995003408A1 (fr) * | 1993-07-26 | 1995-02-02 | Dana-Farber Cancer Institute | B7-2: contre-recepteur de ctla4/cd28 |
| WO1995005464A1 (fr) * | 1993-08-16 | 1995-02-23 | Arch Development Corporation | B7-2: contre recepteur de ctla4/cd28 |
| WO1996014865A1 (fr) * | 1994-11-10 | 1996-05-23 | Repligen Corporation | Procedes d'inhibition de la reaction du greffon contre l'hote lors d'une greffe de moelle osseuse |
Non-Patent Citations (2)
| Title |
|---|
| CAMERON M.J. ET AL: "Cytokine- and costimulation-mediated therapy of IDDM", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 17, no. 5-6, 1997, pages 537 - 544, XP002061663 * |
| LENSCHOW D.J. ET AL: "CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes", IMMUNITY, vol. 5, no. 3, 1996, pages 285 - 293, XP002061664 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1125585A1 (fr) * | 1999-08-30 | 2001-08-22 | Japan Tobacco Inc. | Traitements de maladies immunitaires |
| EP1125585A4 (fr) * | 1999-08-30 | 2007-08-29 | Japan Tobacco Inc | Traitements de maladies immunitaires |
| US7465445B2 (en) | 1999-08-30 | 2008-12-16 | Japan Tobacco Inc. | Methods of preventing or treating graft versus host reaction by administering an antibody or portion thereof that binds to AILIM |
| US7998478B2 (en) | 1999-08-30 | 2011-08-16 | Japan Tobacco, Inc. | Pharmaceutical composition for treating immune diseases |
| US7531168B2 (en) | 2001-02-16 | 2009-05-12 | Genetics Institute Llc | Method for downmodulating immune response in type I diabetes |
| WO2003078468A2 (fr) * | 2002-03-13 | 2003-09-25 | Tegenero Ag | Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique |
| WO2003078468A3 (fr) * | 2002-03-13 | 2004-02-12 | Tegenero Ag | Utilisation d'une substance active se liant a cd28 pour la preparation d'une composition pharmaceutique |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1015016A1 (fr) | 2000-07-05 |
| CA2194814A1 (fr) | 1998-07-10 |
| AU5546298A (en) | 1998-08-03 |
| US6841152B1 (en) | 2005-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arreaza et al. | Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. | |
| KR100496307B1 (ko) | 사람b7.1및/또는b7.2영장류화된형태에특이적인원숭이모노클로날항체및이것의약제학적조성물 | |
| JP2974415B2 (ja) | 組織又は器官移植片にｔ細胞耐性を誘発するための方法 | |
| US7829534B2 (en) | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | |
| US20080305092A1 (en) | Methods of treating autoimmune disease via CTLA-4IG | |
| KR20100126811A (ko) | 모노클로날 항체 및 그것의 방법 | |
| US20080095774A1 (en) | Agents and Methods for Specifically Blocking CD28-Mediated Signaling | |
| JP2002502823A (ja) | 移植における補刺激遮断および混合キメラ現象 | |
| JP5898260B2 (ja) | 併用療法におけるｃｄ８３の使用 | |
| EP1664122B1 (fr) | Des anticorps humanisés therapeutiques contre des isoformes de cd45 | |
| EP1051191B1 (fr) | THERAPIE DE BLOCAGE PAR CD154 POUR TRANSPLANTATION DE TISSUS D'ILOTS PANCREATIQUES chez les primates | |
| US6841152B1 (en) | Methods for protecting against autoimmune diabetes | |
| CA2276733A1 (fr) | Procedes et compositions de prevention de maladies auto-immunes | |
| AU764015B2 (en) | Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists | |
| AU2003261499B2 (en) | Ex vivo treatment of allogeneic and xenogeneic T-cells with gp39 antagonists | |
| WO2001000679A2 (fr) | Procedes permettant d'induire une tolerance des cellules t a une greffe de tissu ou d'organe | |
| Lees | The role of granulocyte macrophage-colony stimulating factor in insulin dependent diabetes mellitus in the non-obese diabetic mouse | |
| Teng | Analysis of the mechanism (s) of immunological tolerance to a physiological soluble antigen in transgenic mice | |
| Anderson | The B7: CD28/CTLA-4 costimulatory pathway in human T cell activation and multiple sclerosis | |
| WO2001030377A1 (fr) | Proteines porcines b7-1 et leurs anticorps | |
| PL191122B1 (pl) | Zastosowania przerywacza wiązania CD40:CD154 | |
| MXPA96005051A (en) | Methods to induce tolerance to t cells for a tissue grafting uórg | |
| CZ461699A3 (cs) | Použití činidla rušícího vazbu CD40:CD154 pro přípravu léku k zabránění odhojení štěpu tkáně tvořící inzulín |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| ENP | Entry into the national phase |
Ref document number: 2276733 Country of ref document: CA Kind code of ref document: A Ref document number: 2276733 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998900502 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 09341407 Country of ref document: US |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref document number: 1998530430 Country of ref document: JP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998900502 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998900502 Country of ref document: EP |